Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Tuesday, December 6, 2022 · 604,988,337 Articles · 3+ Million Readers

Global Anti-Hypertensive Drugs Market Growth Trajectory

Anti-Hypertensive Drugs Global Market Report 2022 - Market Size, Trends, And Global Forecast 2022-2026

Anti-Hypertensive Drugs Global Market Report 2022 - Market Size, Trends, And Global Forecast 2022-2026

Global Anti-Hypertensive Drugs Market Report by TBRC covers anti-hypertensive drugs market size, drivers, restraints, key players, and the impact of COVID-19.

LONDON, GREATER LONDON, UK, September 23, 2022 / -- As per The Business Research Company's "Anti-Hypertensive Drugs Global Market Report 2022”, the anti-hypertensive drugs market is expected to grow from $35.61 billion in 2021 to $37.47 billion in 2022 at a compound annual growth rate (CAGR) of 5.2%. The growth in the anti-hypertensive drugs global market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-hypertensive drug market size is expected to reach $42.85 billion in 2026 at a CAGR of 3.4%. Sedentary lifestyle is a major driver for the growth of the anti-hypertensive drugs market.

Request A Sample Now To Gain A Better Understanding Of Anti-hypertensive Drugs Market:

Key Trends In The Anti-Hypertensive Drugs Market
Of late, there has been rise in use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of a hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When the two drugs are combined with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well.

Overview Of The Anti-Hypertensive Drugs Market
The anti-hypertensive drugs market consists of sales of anti-hypertensive drugs and related services. These drugs are re used to prevent heart failure, kidney failure and acute stroke induced by hypertension. Some of the major anti-hypertensive drugs include diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor antagonists.

Learn More On The Global Anti-hypertensive Drugs Market Report At:

Anti-hypertensive Drugs Global Market Report 2022 From TBRC Covers The Following Information:

Market Size Data
Forecast period: Historical and Future
By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Market Segmentation
By Therapeutic: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators
By Disease Source: Primary Hypertension, Secondary Hypertension
By End-User: Hospitals, Clinics, Homecare
By Geography: The global anti-hypertensive drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market.

Major market players such as Merck & Co. Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, Sun Pharmaceuticals LLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Roche, Abbott, Gilead, Actelion, and Teva Pharmaceutical Industries Ltd.

Trends, Opportunities, Strategies And So Much More.

Anti-Hypertensive Drugs Global Market Report 2022 is one of The Business Research Company’s comprehensive reports that provides an overview of anti-hypertensive drugs market. The market report analyzes anti-hypertensive drugs global market size, anti-hypertensive drugs market growth drivers, anti-hypertensive drugs market segments, anti-hypertensive drugs global market major players, anti-hypertensive drugs market growth across geographies, anti-hypertensive drugs global market trends and anti-hypertensive drugs global market competitors’ revenues and market positioning. The anti-hypertensive drugs global market research report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential.

Not What You Were Looking For? Go Through Similar Reports By The Business Research Company:

Diuretics Global Market Report 2022

Pharmaceutical Drugs Global Market Report 2022

Pharmaceuticals Global Market Report 2022

About The Business Research Company?
The Business Research Company has published over 3000 industry reports, covering over 3000 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Check Out Our:
TBRC Blog:

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:

Market Research Products, Services, Solutions For Your Business - TBRC

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release